QUALITY OVER QUANTITY, AN EXPERT-BASED EVALUATION
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
Last week, EMA approved Strimvelis for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). It is the second genetic therapy approved by EMA after Glybera was cleared in 2012. The usual discussion goes around rarity, investment and pricing, which have been set at very high levels with a few unknowns on efficacy and long term safety. But it has to raise a parallel question, from the industrial and economic perspective.
El Col·legi de Metges de Barcelona (COMB) i Health Innovation Technology Transfer (HITT) han signat un acord de col·laboració per a la realització de l’estudi “La valoració del finançament de les malalties rares”, amb l’objectiu de disposar d’una eina que ajudi al desenvolupament de millors i més adequades polítiques de salut en aquest àmbit.